Observations placeholder

Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.

Unfortunately one of its side effects is inflammation of the gastrointestinal tract.

On Oct, 21, 2017  385,672 people reported to have side effects when taking Humira.
Among them, 11,910 people (3.09%) have Crohns disease

Time on Humira when people have Crohns disease *:

• < 1 month: 28.9 %
• 1 - 6 months: 25.13 %
• 6 - 12 months: 13.28 %
• 1 - 2 years: 15.05 %
• 2 - 5 years: 14.09 %
• 5 - 10 years: 3.28 %
• 10+ years: 0.27 %

Gender of people who have Crohns disease when taking Humira *:

• female: 62.08 %
• male: 37.92 %

Age of people who have Crohns disease when taking Humira *:

• 0-1: 0.01 %
• 2-9: 0.59 %
• 10-19: 13.13 %
• 20-29: 20.65 %
• 30-39: 18.19 %
• 40-49: 17.01 %
• 50-59: 17.12 %
• 60+: 13.27 %

Top conditions involved for these people *:

• Pain (746 people, 6.26%)
• Gastroesophageal Reflux Disease (568 people, 4.77%)
• High Blood Pressure (567 people, 4.76%)
• Depression (566 people, 4.75%)
• Stress And Anxiety (491 people, 4.12%)

Top co-used drugs for these people *:

• Prednisone (814 people, 6.83%)
• Remicade (721 people, 6.05%)
• Methotrexate (628 people, 5.27%)
• Imuran (506 people, 4.25%)
• Pentasa (484 people, 4.06%)

Top other side effects for these people *:

• Drug Ineffective (1,731 people, 14.53%)
• Diarrhea (1,597 people, 13.41%)
• Abdominal Pain (1,455 people, 12.22%)
• Nausea (957 people, 8.04%)
• Nausea And Vomiting (871 people, 7.31%)